A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Non Small Cell Lung Cancer

In brief

Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.

Key facts

Study ID

NCT01562015

Run by

Synta Pharmaceuticals Corp.

People needed

12

Starts

2012-04-01

Expected to finish

2014-11-01

Last updated by the study team

2015-05-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females aged 18 years or older
• Pathological confirmation of advanced NSCLC
• Evidence of a translocation or an inversion event involving the ALK gene locus
• ECOG Performance Status 0 or 1

You may not qualify if…

• Prior therapy with ALK-targeted agents
• Prior treatment with Hsp90 inhibitor
• Known EGFR activating mutation
• Presence of active or untreated central nervous system (CNS) metastases

Where it is running

• Synta Pharmaceuticals Investigative Site — Tampa, Florida, United States
• Synta Pharmaceuticals Investigative Site — Cleveland, Ohio, United States
• Synta Pharmaceuticals Investigative Site — Hamilton, Ontario, Canada
• Synta Pharmaceuticals Investigative Site — Ottawa, Ontario, Canada
• Synta Pharmaceuticals Investigative Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.